Desogestrel
Azalia and Solgest are different trade names for the same drug.
Azalia is used to prevent pregnancy.
Azalia contains a small amount of one type of female sex hormone, progestogen, called desogestrel. For this reason, Azalia is called a progestogen-only pill or a minipill. Unlike the combined contraceptive pill, the progestogen-only pill or minipill does not contain estrogen, only progestogen. Most progestogen-only pills or minipills work primarily by preventing sperm from entering the uterus, but they do not always prevent egg maturation, which is the main action of combined contraceptives. Azalia differs from other minipills in that its dose is usually sufficient to prevent egg maturation. As a result, Azalia has high contraceptive efficacy. Unlike combined oral contraceptives, Azalia can be used by women who do not tolerate estrogens and by breastfeeding women. The disadvantage of using Azalia is the occurrence of irregular bleeding from the genital tract during tablet use. Bleeding may also not occur at all.
Page 1 of 9
Azalia does not protect against HIV (AIDS) or any other sexually transmitted disease.
Azalia should not be used in any of the following cases. Before starting Azalia, the doctor should be informed if any of the following conditions occur. The doctor may recommend the use of a non-hormonal method of birth control.
If any of the above conditions occur for the first time while using Azalia, the doctor should be consulted immediately.
Before starting Azalia, the doctor or pharmacist should be consulted. If Azalia is used in any of the following cases, close monitoring is recommended. The doctor will explain how to proceed. Before starting Azalia, the doctor should be informed:
Breast cancer
Regular breast exams should be performed and the doctor should be consulted immediately if any lump is felt in the breast.
Breast cancer occurs slightly more often in women taking contraceptive pills than in women of the same age who do not take them.
After stopping the use of contraceptive pills, the risk gradually decreases.
Ten years after stopping the use of contraceptive pills, the risk is the same as in women who have never taken contraceptive pills. Breast cancer rarely occurs in women under 40 years of age, but the risk of its occurrence increases with the patient's age. Therefore, the number of diagnosed breast cancer cases is higher, the older the patient is when they stop taking contraceptive pills.
The duration of contraceptive pill use is of less importance.
Page 2 of 9
For every 10,000 women taking contraceptive pills for 5 years who stopped using the medicine before the age of 20, there will be less than 1 additional case of breast cancer diagnosed within 10 years of stopping the pills, compared to 4 cases diagnosed in this age group. Similarly, for every 10,000 women taking contraceptive pills for 5 years who stopped using the medicine before the age of 30, there will be 5 additional cases of breast cancer out of more than 44 cases diagnosed normally. For every 10,000 women taking contraceptive pills for 5 years who stopped using the medicine before the age of 40, there will be 20 additional cases out of more than 160 cases diagnosed normally.
It is believed that the risk of breast cancer in women taking progestogen-only pills, such as Azalia, is similar to the risk in women taking combined contraceptive pills, but the data is not conclusive.
It appears that in women taking contraceptive pills, the detected breast cancer is usually less advanced than in women who do not take contraceptive pills.
It is not known whether this difference is caused by the use of contraceptive pills. The reason for the earlier diagnosis of breast cancer may be that women taking contraceptive pills are examined more frequently.
Thrombosis
The doctor should be consulted immediately if potential symptoms of thrombosis are observed (see also "When to consult a doctor immediately").
Thrombosis is the formation of blood clots that can block a blood vessel.
Thrombosis sometimes occurs in the deep veins of the lower limbs (deep vein thrombosis). If the clot breaks loose from the place in the vein where it formed, it can reach the lungs and block the artery.
This condition is called "pulmonary embolism". As a result, a life-threatening condition can occur, which can lead to death. Deep vein thrombosis is rare and can occur regardless of whether or not contraceptive pills are used. It can also occur during pregnancy.
The risk of occurrence is higher in women taking contraceptive pills than in women who do not take them. The risk of using progestogen-only pills, such as Azalia, is likely to be lower than when using combined contraceptive pills.
Mental disorders:
Some women taking hormonal contraceptives, including Azalia, have reported depression or low mood. Depression can be severe and sometimes lead to suicidal thoughts. If mood changes and symptoms of depression occur, the doctor should be consulted as soon as possible for further medical advice.
The safety and efficacy of desogestrel in adolescents under 18 years of age have not been established. Data is not available.
The doctor or pharmacist should be told about all medicines currently being taken or recently taken, as well as any medicines planned to be taken.
The patient should also inform other doctors or dentists who prescribe other medicines (or pharmacists) that they are taking Azalia.
The doctor will inform the patient whether there is a need to use an additional contraceptive method (e.g., a condom) and if so, for how long and whether there is a need to change the dosage of other medicines being taken.
Some medicines:
Page 3 of 9
These are medicines used to treat:
If the patient is taking medicines or herbal products that may cause Azalia to be less effective, an additional barrier method of contraception should be used. Since the effect of another medicine on Azalia may last up to 28 days after its discontinuation, prolonged use of an additional barrier method of contraception is necessary. The doctor may inform the patient whether there is a need to use additional contraceptive measures and if so, for how long.
Azalia may also affect the action of other medicines, causing an increase in their action (e.g., medicines containing cyclosporine) or a decrease in their action (e.g., lamotrigine).
Before taking any medicine, the doctor or pharmacist should be consulted.
If the patient is pregnant or breastfeeding, suspects they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before using this medicine.
Azalia should not be used if the patient is pregnant or suspects they may be pregnant.
Azalia can be used during breastfeeding. It does not appear to affect milk production or the quality of the milk secreted. However, a decrease in milk production has occasionally occurred during Azalia use. Small amounts of the active substance of Azalia pass into breast milk. In children who were breastfed for 7 months by mothers taking desogestrel, the effect on health was investigated up to the age of 2.5 years. No effect on the growth and development of children was observed.
The doctor should be consulted if a breastfeeding woman wants to use Azalia.
Azalia does not affect the ability to drive or use machines.
Patients with lactose intolerance should be aware that Azalia tablets contain 52.34 mg of lactose (in the form of lactose monohydrate).
If lactose intolerance has been previously diagnosed in the patient, the patient should consult a doctor before taking the medicine.
During Azalia use, the doctor will ask the patient to come in for regular check-ups. The frequency and type of check-ups will depend on the patient's health status.
Page 4 of 9
unexplained chest pain, shortness of breath, unusual cough, especially coughing up blood (indicating a possible thrombosis);
This medicine should always be used as directed by the doctor.
In case of doubts, the doctor or pharmacist should be consulted.
Each Azalia blister pack contains 28 tablets. Arrows and abbreviations of the days of the week are printed on the front of the blister pack, which allows for proper use of the medicine.
It is recommended to take the medicine every day at the same time.
The tablet should be swallowed whole, with water.
Each time a new Azalia blister pack is started, the tablet should be taken from the top row. For example, if tablet use starts on a Wednesday, the tablet from the top row marked Mi (Mi - Wednesday, see "Translation of day of the week abbreviations on the packaging" at the end of the leaflet) should be taken.
One tablet should be taken every day, until the blister pack is empty, always in the direction indicated by the arrows. If the patient starts taking tablets on a Monday, the end of the arrow on the blister pack will be empty, but in any other case, before starting a new blister pack, the tablets in the top left corner of that blister pack should be taken.
This way, it is easy to check if a tablet has been taken on a given day. During Azalia use, bleeding may occur (see "Possible side effects"), but tablet use should be continued as usual.
After finishing a blister pack, the next Azalia pack should be started the next day - without interruption and without waiting for bleeding.
If you are not using (or have not used in the last month) hormonal contraceptives
Wait for the menstrual period to start.
On the first day of the menstrual period, take the first Azalia tablet.
There is no need to use other contraceptive methods.
Tablet use can also be started between the 2nd and 5th day of the cycle, but in such cases, additional contraceptive methods (barrier method) should be used for the first 7 days of tablet use.
Switching from a combined contraceptive pill, vaginal ring, or transdermal patch
Azalia use can be started the next day after taking the last tablet from the current contraceptive pack or on the day the vaginal ring or transdermal patch is removed (this means no break in contraceptive use).
If the current contraceptive pack contains tablets without active ingredients, Azalia use can be started the next day after taking the last tablet containing active ingredients (if in doubt, consult a doctor or pharmacist). If the above instructions are followed, there is no need to use additional contraceptive methods.
Azalia use can be started at the latest on the day after the break in tablet use, vaginal ring use, or after the transdermal patch is removed. In this case, additional contraceptive methods (barrier methods) should be used for the first 7 days of tablet use.
Switching from another progestogen-only pill (minipill)
Azalia use can be started on any day, immediately after stopping the previous progestogen-only pill. There is no need to use additional contraceptive methods.
Switching from an injection, implant, or intrauterine system releasing progestogen (IUD)
Azalia use should be started on the day the next injection is scheduled or on the day the implant or intrauterine system is removed. There is no need to use additional contraceptive methods.
After childbirth
Azalia use can be started between 21 and 28 days after childbirth. If Azalia use is started later, an additional barrier method of contraception should be used during the first cycle for the first 7 days of tablet use.
However, if there has been sexual intercourse, pregnancy should be ruled out before starting Azalia. Additional information for breastfeeding women can be found in the "Pregnancy and breastfeeding" subsection in section 2. The doctor should also be consulted.
After premature birth or miscarriage
The doctor should be consulted.
If the delay in taking a tablet is less than 12 hours
The missed tablet should be taken as soon as remembered, and the next tablet should be taken at the usual time. The contraceptive effect of Azalia is maintained.
If the delay in taking a tablet is more than 12 hours
The missed tablet should be taken as soon as remembered, and the next tablet should be taken at the usual time. This may mean taking two tablets on the same day. This is not a problem. (If more than one tablet is missed, there is no need to make up for the previously missed tablets). In this case, there is a possibility of pregnancy.
Tablet use should be continued as usual, and an additional contraceptive method should be used, e.g., a condom, for the next 7 days.
The more consecutive tablets are missed, the higher the risk of reduced contraceptive efficacy.
If one or more tablets are missed in the first week of use and there has been sexual intercourse in the week preceding the missed tablets, there is a possibility of pregnancy.
The doctor should be consulted for advice.
If there are vomiting, diarrhea, or activated charcoal is used
In case of vomiting or severe diarrhea or if activated charcoal is used 3-4 hours after taking a tablet, there is a risk that the active substance may not have been fully absorbed. The instructions for missing a tablet should be followed.
No serious harmful effects have been observed after taking many Azalia tablets at the same time. Symptoms such as nausea, vomiting, and, in young girls, slight vaginal bleeding may occur. For further information, the doctor should be consulted.
Azalia use can be stopped at any time.
Starting from the day Azalia use is stopped, the patient is no longer protected against pregnancy.
In case of any further doubts about using this medicine, the doctor or pharmacist should be consulted.
Like all medicines, Azalia can cause side effects, although not everybody gets them.
Serious side effects related to Azalia use have been described in section 2 "Important information before using Azalia". These sections should be read to obtain additional information and, if necessary, consult a doctor.
The doctor should be consulted immediatelyif allergic reactions occur (hypersensitivity), including swelling of the face, lips, tongue, and/or throat causing difficulty breathing or swallowing (angioedema and/or anaphylaxis) (the frequency of this side effect cannot be determined based on available data).
During Azalia use, irregular vaginal bleeding may occur. This can be slight spotting, not requiring even the use of a sanitary pad, or more severe bleeding, similar to a light menstrual period, requiring the use of a sanitary pad. Bleeding may also not occur at all. These are common side effects (may occur in up to 1 in 10 patients). Irregular bleeding does not mean that the contraceptive effect of Azalia is reduced. In general, there is no need to take any action, and Azalia use should be continued as usual. However, if the bleeding is heavy or prolonged, the doctor should be consulted.
Patients taking desogestrel have reported the following other side effects:
Common(may occur in up to 1 in 10 patients):
Uncommon(may occur in up to 1 in 100 patients):
Page 7 of 9
In addition to the listed side effects, milk leakage or discharge may occur.
If any side effects occur, including any side effects not listed in the leaflet, the doctor, pharmacist, or nurse should be informed. Side effects can be reported directly to the Department of Drug Adverse Reaction Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.
Store in the original packaging to protect from light and moisture.
No special storage temperature instructions.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer used. This will help protect the environment.
The active substance of Azalia is desogestrel. One tablet contains 75 micrograms of desogestrel.
The other ingredients are:
Tablet core:
Lactose monohydrate,
Potato starch,
Povidone K 30,
Colloidal anhydrous silica,
Stearic acid,
All-rac-α-tocopherol.
Tablet coating:
Polyvinyl alcohol,
Titanium dioxide (E 171),
Macrogol 3000,
Talc.
Page 8 of 9
White or almost white, round, biconvex, film-coated tablets with a diameter of about 5.5 mm, marked with the letter "D" on one side and "75" on the other side.
Azalia, 75 micrograms, film-coated tablets are packaged in PVC/PVDC//Aluminum blisters, each packaged separately in a laminated aluminum sachet, in a cardboard box
The sachets with blisters are packaged in a cardboard box with a patient leaflet and a laminated aluminum sachet for storage.
A cardboard sachet has been added to the packaging, in which the blister should be placed after being removed from the laminated aluminum sachet.
Pack sizes: 28 film-coated tablets, 84 film-coated tablets (3 blisters of 28 tablets).
For more detailed information, the marketing authorization holder or parallel importer should be consulted.
Chemical Works of Gedeon Richter Plc., Gyömroi út 19-21, 1103 Budapest, Hungary
Chemical Works of Gedeon Richter Plc., Gyömroi út 19-21, 1103 Budapest, Hungary
Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
German marketing authorization number: 81269.00.00
Azalia 75 microgram filmtabletta, Hungary
Azalia 75 microgram potahovaná tableta, Czech Republic
Azalia 75 mikrogram filmom obalené tablety, Slovakia
Azalia, Poland
Azalia 75 microgram plėvele dengtos tabletės, Lithuania
Azalia 75 mikrogram apvalkotā tablete, Latvia
Tangolita, Denmark
Азалия 75 мигрограма филмирани таблетки, Bulgaria
Azalia 75 micrograme comprimate filmate, Romania
Mo
[Information about the trademark]
Page 9 of 9
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.